Nicholas Augustinos Sells 1,550 Shares of DexCom (NASDAQ:DXCM) Stock

September 17, 2026 by InsiderTrades.com

Key Points

Director Nicholas Augustinos sold 6,539 DexCom shares at an average price of $84.04, generating approximately $549,538. The Rule 10b5-1 transaction reduced his holdings by 18.25%, leaving him with 29,293 shares.
DexCom’s latest quarterly results exceeded expectations, with adjusted earnings of $0.70 per share versus a $0.61 consensus estimate and revenue of $1.31 billion, up 13.1% year over year.
Analysts maintain a generally positive view, with a “Moderate Buy” consensus rating and an average price target of $88.71, although recent insider selling may create some short-term caution.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Nicholas Augustinos sold 1,550 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $84.02, for a total value of $130,231.00. Following the completion of the transaction, the director directly owned 35,832 shares in the company, valued at approximately $3,010,604.64. This trade represents a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

Nicholas Augustinos also recently made the following trade(s):

On Tuesday, September 15th, Nicholas Augustinos sold 6,539 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total value of $549,537.56.

DexCom Price Performance

Shares of DXCM stock opened at $87.34 on Thursday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The stock has a market capitalization of $32.96 billion, a price-to-earnings ratio of 34.52, a P/E/G ratio of 1.45 and a beta of 1.42. The stock has a fifty day simple moving average of $83.52 and a two-hundred day simple moving average of $73.07. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 earnings per share. On average, analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

Positive Sentiment: Expanded leadership role: CFO Jereme Sylvain will also serve as chief operating officer, potentially improving coordination between DexCom’s financial and operational functions as the company expands its continuous glucose-monitoring business. DexCom CFO Jereme Sylvain to Take Additional Role of COO
Positive Sentiment: Strong recent financial results: DexCom’s latest quarterly report exceeded expectations, with earnings per share of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, supporting the growth outlook for its G7 and other CGM products.
Positive Sentiment: Generally favorable analyst view: The stock carries a “Moderate Buy” consensus rating, with recent bullish targets including $95 from Stifel, $96 from UBS and $105 from Robert W. Baird. The average published target is $88.71, suggesting relatively limited but still positive upside based on the cited estimates.
Neutral Sentiment: Insider selling appears scheduled: EVP Michael Brown sold 1,700 shares, while Director Nicholas Augustinos sold a combined 8,089 shares. Because the transactions were conducted under pre-arranged trading plans, they may reflect routine diversification rather than a negative view of DexCom’s prospects. DexCom insider transaction filing
Negative Sentiment: Multiple insider sales could weigh on sentiment: The recent sales, including EVP Jereme Sylvain’s disposal of 3,638 shares for approximately $303,000, add a short-term cautionary signal even though the executives retained substantial holdings. DexCom insider selling report

Wall Street Analysts Forecast Growth

Sell in May and Go Away—Starting With These 3 Stocks

Several equities research analysts have recently weighed in on the stock. Argus upped their price target on shares of DexCom from $86.00 to $96.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of DexCom from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 11th. Royal Bank Of Canada upped their target price on DexCom from $85.00 to $90.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research report on Sunday, September 6th. Finally, Mizuho lifted their price target on DexCom from $90.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $88.71.

Get Our Latest Stock Report on DXCM

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of DexCom by 15.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company's stock worth $758,487,000 after purchasing an additional 1,515,702 shares in the last quarter. Geode Capital Management LLC raised its stake in DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company's stock valued at $727,842,000 after purchasing an additional 42,411 shares during the last quarter. Norges Bank acquired a new stake in DexCom during the 4th quarter worth $483,356,000. Legal & General Group Plc purchased a new stake in shares of DexCom during the second quarter worth $173,237,000. Finally, Janus Henderson Group PLC raised its position in shares of DexCom by 32.3% in the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company's stock valued at $166,077,000 after buying an additional 645,534 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

(Get Free Report)

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.